427 related articles for article (PubMed ID: 20688050)
1. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
2. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
3. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
Fujita N
Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
[TBL] [Abstract][Full Text] [Related]
4. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
6. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
7. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
8. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
Leger DY; Liagre B; Beneytout JL
Apoptosis; 2006 Oct; 11(10):1747-60. PubMed ID: 16927021
[TBL] [Abstract][Full Text] [Related]
9. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
10. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy.
Fan M; Chambers TC
Drug Resist Updat; 2001 Aug; 4(4):253-67. PubMed ID: 11991680
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt signalling pathway and cancer.
Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy.
Zhao YW; Jin L; Li ZM; Zhao CJ; Wei YQ; Yang HS
Cancer Sci; 2011 Aug; 102(8):1469-75. PubMed ID: 21561530
[TBL] [Abstract][Full Text] [Related]
13. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway.
Saleem M; Kaur S; Kweon MH; Adhami VM; Afaq F; Mukhtar H
Carcinogenesis; 2005 Nov; 26(11):1956-64. PubMed ID: 15958516
[TBL] [Abstract][Full Text] [Related]
14. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
Lue H; Thiele M; Franz J; Dahl E; Speckgens S; Leng L; Fingerle-Rowson G; Bucala R; Lüscher B; Bernhagen J
Oncogene; 2007 Aug; 26(35):5046-59. PubMed ID: 17310986
[TBL] [Abstract][Full Text] [Related]
15. 16-Hydroxycleroda-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis.
Lin YH; Lee CC; Chan WL; Chang WH; Wu YC; Chang JG
Toxicology; 2011 Jul; 285(1-2):72-80. PubMed ID: 21530604
[TBL] [Abstract][Full Text] [Related]
16. Targeting AKT protein kinase in gastric cancer.
Almhanna K; Strosberg J; Malafa M
Anticancer Res; 2011 Dec; 31(12):4387-92. PubMed ID: 22199303
[TBL] [Abstract][Full Text] [Related]
17. Targeting PI3K-AKT pathway for cancer therapy.
Lu Y; Wang H; Mills GB
Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
[TBL] [Abstract][Full Text] [Related]
18. Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway.
Cossa G; Gatti L; Cassinelli G; Lanzi C; Zaffaroni N; Perego P
Curr Pharm Des; 2013; 19(5):883-94. PubMed ID: 22973957
[TBL] [Abstract][Full Text] [Related]
19. Survival-signaling pathway as a promising target for cancer chemotherapy.
Fujita N; Tsuruo T
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S24-8. PubMed ID: 12819931
[TBL] [Abstract][Full Text] [Related]
20. Ribozymes targeting serine/threonine kinase Akt1 sensitize cells to anticancer drugs.
Yanagihara M; Katano M; Takahashi-Sasaki N; Kimata K; Taira K; Andoh T
Cancer Sci; 2005 Sep; 96(9):620-6. PubMed ID: 16128748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
